ALNY
Alnylam Pharmaceuticals, Inc.
Stock
$219.72−11.46 (−4.96%)Close Oct 2, 2026
Key figures
| Metric | Last 12 months | 5-year CAGR |
|---|---|---|
| Revenue | $4.8B | +49.8% |
| Gross profit | $3.8B | +48.6% |
| Operating income | $1,000M | — |
| Net income | $733M | — |
| EPS | $5.74 | — |
| Free cash flow | $820M | — |